Literature DB >> 32239794

Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction.

Javed Butler1, Muhammad Shahzeb Khan2, Claudio Mori3, Gerasimos S Filippatos4,5, Piotr Ponikowski6, Josep Comin-Colet7, Bernard Roubert3, John A Spertus8, Stefan D Anker9.   

Abstract

AIMS: While the associations of health-related quality of life scores in heart failure (HF) [e.g. the Kansas City Cardiomyopathy Questionnaire (KCCQ)] with clinical outcomes are well established, their interpretation in the context of what magnitudes of change are clinically important to patients is less clear. The main objective of this study was to correlate the changes in the KCCQ and Patient Global Assessment (PGA) in patients with HF with reduced ejection fraction (HFrEF) to determine minimal clinically important difference (MCID). METHODS AND
RESULTS: We analysed data from 459 patients of the FAIR-HF trial. Both KCCQ and PGA were assessed at 4 and 24 weeks after enrolment. An anchor-based approach was used to calculate MCID at week 4 and 24. PGA was chosen as the clinical anchor against which changes in the KCCQ scores were calibrated. For each category of change in PGA, the corresponding differences were calculated by the mean scores of various domains of KCCQ along with 95% confidence intervals (CIs). There was fair correlation between PGA and changes in overall summary scores (OSS) (r = 0.31; P < 0.001), clinical summary scores (CSS) (r = 0.36; P < 0.001) and physical limitation scores (PLS) (r = 0.31; P < 0.001) from baseline to week 4. KCCQ OSS, CSS and PLS MCID for 'little improvement' at week 4 were 3.6 (1.0-6.2), 4.5 (1.8-7.2) and 4.7 (1.4-8.0) points, respectively. OSS, CSS and PLS MCID for 'little improvement' at week 24 were 4.3 (0.2-8.4), 4.5 (0.5-8.5) and 4.0 (-0.9-9.0) points, respectively.
CONCLUSION: The MCID threshold for KCCQ score was generally consistent and numerically lower than the threshold of 5-point change considered for clinical outcome prognosis and were stable between 4 and 24 weeks. This suggests that even changes smaller than the traditional 5-point improvements in KCCQ may be clinically meaningful. Also, these results can aid in the clinical interpretation of patient-reported outcomes, and better endpoint selection in future studies.
© 2020 European Society of Cardiology.

Entities:  

Keywords:  Heart failure; Kansas City Cardiomyopathy Questionnaire; Minimal clinically important difference; Patient Global Assessment; Patient-reported outcomes; Quality of life

Mesh:

Year:  2020        PMID: 32239794     DOI: 10.1002/ejhf.1810

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  18 in total

1.  Development and Evaluation of the Eight-Item Caregiver Self-Efficacy Scale (CSES-8).

Authors:  Philip L Ritter; Khushboo Sheth; Anita L Stewart; Dolores Gallagher-Thompson; Kate Lorig
Journal:  Gerontologist       Date:  2022-03-28

2.  Effect of an Early Palliative Care Telehealth Intervention vs Usual Care on Patients With Heart Failure: The ENABLE CHF-PC Randomized Clinical Trial.

Authors:  Marie A Bakitas; J Nicholas Dionne-Odom; Deborah B Ejem; Rachel Wells; Andres Azuero; Macy L Stockdill; Konda Keebler; Elizabeth Sockwell; Sheri Tims; Sally Engler; Karen Steinhauser; Elizabeth Kvale; Raegan W Durant; Rodney O Tucker; Kathryn L Burgio; Jose Tallaj; Keith M Swetz; Salpy V Pamboukian
Journal:  JAMA Intern Med       Date:  2020-09-01       Impact factor: 21.873

3.  Effect of Carillon Mitral Contour System on patient-reported outcomes in functional mitral regurgitation: an individual participant data meta-analysis.

Authors:  Muhammad Shahzeb Khan; Tim Friede; Stefan D Anker; Javed Butler
Journal:  ESC Heart Fail       Date:  2021-03-30

4.  African American Recruitment in Early Heart Failure Palliative Care Trials: Outcomes and Comparison With the ENABLE CHF-PC Randomized Trial.

Authors:  Macy L Stockdill; J Nicholas Dionne-Odom; Rachel Wells; Deborah Ejem; Andres Azuero; Konda Keebler; Elizabeth Sockwell; Sheri Tims; Kathryn L Burgio; Sally Engler; Raegan Durant; Salpy V Pamboukian; Jose Tallaj; Keith M Swetz; Elizabeth Kvale; Rodney Tucker; Marie Bakitas
Journal:  J Palliat Care       Date:  2020-12-01       Impact factor: 1.980

5.  A comprehensive individual patient data meta-analysis of the effects of cardiac contractility modulation on functional capacity and heart failure-related quality of life.

Authors:  Francesco Giallauria; Gianluigi Cuomo; Alessandro Parlato; Nirav Y Raval; Jürgen Kuschyk; Andrew Js Stewart Coats
Journal:  ESC Heart Fail       Date:  2020-07-23

6.  Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.

Authors:  Javed Butler; Stefan D Anker; Gerasimos Filippatos; Muhammad Shahzeb Khan; João Pedro Ferreira; Stuart J Pocock; Nadia Giannetti; James L Januzzi; Ileana L Piña; Carolyn S P Lam; Piotr Ponikowski; Naveed Sattar; Subodh Verma; Martina Brueckmann; Waheed Jamal; Ola Vedin; Barbara Peil; Cordula Zeller; Faiez Zannad; Milton Packer
Journal:  Eur Heart J       Date:  2021-03-31       Impact factor: 29.983

7.  Novel Trial Design: CHIEF-HF.

Authors:  John A Spertus; Mary C Birmingham; Javed Butler; Ildiko Lingvay; David E Lanfear; Antonio Abbate; Mikhail L Kosiborod; Christina Fawcett; Paul Burton; C V Damaraju; James L Januzzi; John Whang
Journal:  Circ Heart Fail       Date:  2021-03-16       Impact factor: 8.790

8.  Effectiveness of motivational interviewing on anxiety, depression, sleep quality and quality of life in heart failure patients: secondary analysis of the MOTIVATE-HF randomized controlled trial.

Authors:  Paola Rebora; Valentina Spedale; Giuseppe Occhino; Michela Luciani; Rosaria Alvaro; Ercole Vellone; Barbara Riegel; Davide Ausili
Journal:  Qual Life Res       Date:  2021-02-22       Impact factor: 4.147

9.  Patient-Reported Outcomes From Patients With Heart Failure Participating in the Future Patient Telerehabilitation Program: Data From the Intervention Arm of a Randomized Controlled Trial.

Authors:  Cathrine Skov Schacksen; Anne-Kirstine Dyrvig; Nanna Celina Henneberg; Josefine Dam Gade; Helle Spindler; Jens Refsgaard; Malene Hollingdal; Lars Dittman; Kim Dremstrup; Birthe Dinesen
Journal:  JMIR Cardio       Date:  2021-07-02

10.  Current challenges for using the Kansas City Cardiomyopathy Questionnaire to obtain a standardized patient-reported health status outcome.

Authors:  Nicolette Stogios; Gabriel Fezza; Julia V Wong; Heather J Ross; Michael E Farkouh; Robert P Nolan
Journal:  Eur J Heart Fail       Date:  2021-03-08       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.